Current Treatment Options in Neurology

, Volume 11, Issue 2, pp 102–110 | Cite as

Stiff person syndrome: Advances in pathogenesis and therapeutic interventions

Article

Opinion statement

Stiff person syndrome (SPS) varies from mild to severe, but if untreated it can be progressive and disabling. Although progress has been made in understanding and treating SPS, the disease remains underdiagnosed, delaying treatment. Antibodies against glutamic acid decarboxylase provide an excellent diagnostic marker, but their role in disease pathogenesis is uncertain. Research focused on identifying new autoantigens has provided evidence that γ-aminobutyric acid (GABA)A receptor-associated protein (GABARAP), a 14-kD protein localized at the postsynaptic regions of GABAergic synapses, is an antigenic target. Circulating anti-GABARAP antibodies that inhibit GABAA receptor expression on GABAergic neurons have been found in up to 65% of SPS patients. The impairment of GABAergic pathways and reduction of brain GABA results in clinical manifestations of stiffness, spasms, and phobias.

Increased awareness of SPS among practicing physicians is necessary to recognize the disease early and prevent permanent disability. Most patients with SPS respond to GABA-enhancing drugs, but the high doses required cause unacceptable adverse effects. The disease clearly responds to intravenous immunoglobulin, but repeated infusions are needed to maintain response. New immunomodulating agents are being explored to treat difficult cases and to induce long-lasting remissions.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Dalakas MC, Fujii M, Li M, McElroy B: The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 2000, 55:1531–1535.PubMedGoogle Scholar
  2. 2.
    Levy LM, Dalakas MC, Floeter MK: The stiff-person syndrome: an autoimmune disorder affecting neurotransmission of gamma-aminobutyric acid. Ann Intern Med 1999, 131:522–530.PubMedGoogle Scholar
  3. 3.
    Spay AJ, Chen R: Rigidity and spasms from autoimmune encephalomyelopathies: stiff-person syndrome. Muscle Nerve 2006, 34:677–690.CrossRefGoogle Scholar
  4. 4.
    Dalakas MC, Li M, Fujii M, Jacobowitz DM: Stiff-person syndrome: quantification, specificity and intrathecal synthesis of GAD65 antibodies. Neurology 2001, 57:780–785.PubMedGoogle Scholar
  5. 5.
    Ameli R, Snow J, Rakocevic G, Dalakas MC: A neuropsychological assessment of phobias in patients with stiff person syndrome. Neurology 2005, 64:1961–1963.PubMedCrossRefGoogle Scholar
  6. 6.
    Vasconcelos OM, Dalakas MC: Therapies for stiff person syndrome. Curr Treat Options Neurol 2003, 5:79–90.PubMedCrossRefGoogle Scholar
  7. 7.
    Barker RA, Revesz T, Thom M, et al.: Review of 23 patients affected by the stiff man syndrome: clinical subdivision into stiff trunk (man) syndrome, stiff limb syndrome, and progressive encephalomyelitis with rigidity. J Neurol Neurosurg Psychiatry 1998, 65:633–640.PubMedCrossRefGoogle Scholar
  8. 8.
    Meinck HM, Ricker K, Hulser PJ, Solimena M: Stiff man syndrome: neurophysiological findings in eight patients. J Neurol 1995, 242:134–142.PubMedCrossRefGoogle Scholar
  9. 9.
    Murinson BB, Butler M, Marfurt K, et al.: Markedly elevated GAD antibodies in SPS: effects of age and illness duration. Neurology 2004, 63:2146–2148.PubMedGoogle Scholar
  10. 10.
    Solimena M, Folli F, Aparisi R, et al.: Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med 1990, 322:1555–1560.PubMedGoogle Scholar
  11. 11.
    Rakocevic G, Raju R, Semino-Mora C, Dalakas MC: Stiff person syndrome with cerebellar disease and high-titer anti-GAD antibodies. Neurology 2006, 67:1068–1070.PubMedCrossRefGoogle Scholar
  12. 12.
    Economides JR, Horton JC: Eye movement abnormalities in stiff person syndrome. Neurology 2005, 65:1462–1464.PubMedCrossRefGoogle Scholar
  13. 13.
    Zivotofsky AZ, Siman-Tov T, Gadoth N, Gordon CR: A rare saccade velocity profile in stiff-person syndrome with cerebellar degeneration. Brain Res 2006, 1093:135–140.PubMedCrossRefGoogle Scholar
  14. 14.
    Whiteley AM, Swash M, Urich H: Progressive encephalomyelitis with rigidity. Brain 1976, 99:27–42.PubMedCrossRefGoogle Scholar
  15. 15.
    De Camilli P, Thomas A, Cofiell R, et al.: The synaptic vesicle-associated protein amphiphysin is the 128-kD autoantigen of stiff-man syndrome with breast cancer. J Exp Med 1993, 178:2219–2223.PubMedCrossRefGoogle Scholar
  16. 16.
    Butler MH, Hayashi A, Ohkoshi N, et al.: Autoimmunity to gephyrin in stiff-man syndrome. Neuron 2000, 26:307–312.PubMedCrossRefGoogle Scholar
  17. 17.
    Ishida K, Mitoma H, Song SY, et al.: Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. Ann Neurol 1999, 46:263–267.PubMedCrossRefGoogle Scholar
  18. 18.
    Sandbrink F, Syed NA, Fujii MD, et al.: Motor cortex excitability in stiff-person syndrome. Brain 2000, 123(Pt 11):2231–2239.PubMedCrossRefGoogle Scholar
  19. 19.
    Levy LM, Levy-Reis I, Fujii M, Dalakas MC: Brain gamma-aminobutyric acid changes in stiff-person syndrome. Arch Neurol 2005, 62:970–974.PubMedCrossRefGoogle Scholar
  20. 20.
    Ellis MT, Atkinson AM: The clinical significance of an autoimmune response against glutamic acid decarboxylase. Nat Med 1996, 2:148–153.PubMedCrossRefGoogle Scholar
  21. 21.
    Daw K, Ujihara N, Atkinson M, Powers AC: Glutamic acid decarboxylase autoantibodies in stiff-man syndrome and insulin-dependent diabetes mellitus exhibit similarities and differences in epitope recognition. J Immunol 1996, 156:818–825.PubMedGoogle Scholar
  22. 22.
    Dalakas MC: The role of IVIg in the treatment of patients with stiff person syndrome and other neurological diseases associated with anti-GAD antibodies. J Neurol 2005, 252(Suppl 1):I19–I25.PubMedCrossRefGoogle Scholar
  23. 23.
    Peltola J, Kulmala P, Isojarvi J, et al.: Autoantibodies to glutamic acid decarboxylase in patients with therapyresistant epilepsy. Neurology 2000, 55:46–50.PubMedGoogle Scholar
  24. 24.
    Honnorat J, Saiz A, Giometto B, et al.: Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 2001, 58:225–230.PubMedCrossRefGoogle Scholar
  25. 25.
    Vulliemoz S, Vanini G, Truffert A, et al.: Epilepsy and cerebellar ataxia associated with anti-glutamic acid decarboxylase antibodies. J Neurol Neurosurg Psychiatry 2007, 78:187–189.PubMedCrossRefGoogle Scholar
  26. 26.
    Antozzi C, Frassoni C, Vincent A, et al.: Sequential antibodies to potassium channels and glutamic acid decarboxylase in neuromyotonia. Neurology 2005, 64:1290–1293.PubMedGoogle Scholar
  27. 27.
    Vernino S, Lennon VA: Autoantibody profiles and neurological correlations of thymoma. Clin Cancer Res 2004, 10:7270–7275.PubMedCrossRefGoogle Scholar
  28. 28.
    Pearce DA, Atkinson M, Tagle DA: Glutamic acid decarboxylase autoimmunity in Batten disease and other disorders. Neurology 2004, 63:2001–2005.PubMedGoogle Scholar
  29. 29.
    Dinkel K, Meinck HM, Jury KM, et al.: Inhibition of gamma-aminobutyric acid synthesis by glutamic acid decarboxylase autoantibodies in stiff-man syndrome. Ann Neurol 1998, 44:194–201.PubMedCrossRefGoogle Scholar
  30. 30.
    Raju R, Foote J, Banga JP, et al.: Analysis of GAD65 autoantibodies in stiff-person syndrome patients. J Immunol 2005, 175:7755–7762.PubMedGoogle Scholar
  31. 31.
    Rakocevic G, Raju R, Dalakas MC: Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity. Arch Neurol 2004, 61:902–904.PubMedCrossRefGoogle Scholar
  32. 32.
    Burns TM, Phillips LH 2nd, Jones HR: Stiff person syndrome does not always occur with maternal passive transfer of GAD65 antibodies. Neurology 2005, 64:399–400.PubMedGoogle Scholar
  33. 33.
    Perani D, Garibotto V, Moresco RM, et al.: PET evidence of central GABAergic changes in stiff-person syndrome. Mov Disord 2007, 22:1030–1033.PubMedCrossRefGoogle Scholar
  34. 34.
    Raju R, Rakocevic G, Chen Z, et al.: Autoimmunity to GABAA-receptor-associated protein in stiff-person syndrome. Brain 2006, 129(Pt 12):3270–3276.PubMedCrossRefGoogle Scholar
  35. 35.
    Leil TA, Chen ZW, Chang CS, Olsen RW: GABAA receptor-associated protein traffics GABAA receptors to the plasma membrane in neurons. J Neurosci 2004, 24:11429–11438.PubMedCrossRefGoogle Scholar
  36. 36.
    Coyle JE, Nikolov DB: GABARAP: lessons for synaptogenesis. Neuroscientist 2003, 9:205–216.PubMedCrossRefGoogle Scholar
  37. 37.
    Murinson BB, Vincent A: Stiff-person syndrome: autoimmunity and the central nervous system. CNS Spectrum 2001, 6:427–433.Google Scholar
  38. 38.
    Hutchinson M, Waters P, McHugh J, et al.: Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology 2008, 71:1291–1292.PubMedCrossRefGoogle Scholar
  39. 39.
    Vincent A: Stiff, twitchy or wobbly: are GAD antibodies pathogenic? [editorial]. Brain 2008, 131:2536–2537.PubMedCrossRefGoogle Scholar
  40. 40.
    Bouw J, Leendertse K, Tijssen MA, Dzoljic M: Stiff person syndrome and anesthesia: case report. Anesth Analg 2003, 97:486–487.PubMedCrossRefGoogle Scholar
  41. 41.
    Ledowski T, Bromilow J, Paech MJ, et al.: Skin conductance monitoring compared with Bispectral Index to assess emergence from total i.v. anaesthesia using propofol and remifentanil. Br J Anaesth 2006, 97:817–821.PubMedCrossRefGoogle Scholar
  42. 42.
    Elkassabany N, Tetzlaff JE, Argalious M: Anesthetic management of a patient with stiff person syndrome. J Clin Anesth 2006, 18:218–220.PubMedCrossRefGoogle Scholar
  43. 43.
    Howard FM Jr: A new and effective drug in the treatment of stiff-man syndrome: preliminary report. Proc Mayo Clin 1963, 38:203–212.Google Scholar
  44. 44.
    Sharoqi IA: Improvement of stiff-man syndrome with vigabatrin. Neurology 1998, 50:833–834.PubMedGoogle Scholar
  45. 45.
    Murinson BB, Rizzo M: Improvement of stiff-person syndrome with tiagabine. Neurology 2001, 57:366.PubMedGoogle Scholar
  46. 46.
    Ruegg SJ, Steck AJ, Fuhr P: Levetiracetam improves paroxysmal symptoms in a patient with stiff-person syndrome. Neurology 2004, 62:338.PubMedGoogle Scholar
  47. 47.
    Silbert PL, Matsumoto JY, McManis PG, et al.: Intrathecal baclofen therapy in stiff-man syndrome: a double-blind, placebo-controlled trial. Neurology 1995, 45:1893–1897.PubMedGoogle Scholar
  48. 48.
    Liguori R, Cordivari C, Lugaresi E, et al.: Botulinum toxin A improves muscle spasms and rigidity in stiff-person syndrome. Mov Disord 1997, 12:1060–1063.PubMedCrossRefGoogle Scholar
  49. 49.
    Dalakas MC, Fujii M, Li M, et al.: High-dose intravenous immunoglobulin for stiff-person syndrome. N Engl J Med 2001, 345:1870–1876.PubMedCrossRefGoogle Scholar
  50. 50.
    Dalakas MC: Invited article: inhibition of B cell functions: implications for neurology. Neurology 2008, 70:2252–2260.PubMedCrossRefGoogle Scholar
  51. 51.
    Dalakas MC: B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008, 4:557–567.PubMedCrossRefGoogle Scholar
  52. 52.
    Baker MR, Das M, Isaacs J, et al.: Treatment of stiff person syndrome with rituximab. J Neurol Neurosurg Psychiatry 2005, 76:999–1001.PubMedCrossRefGoogle Scholar
  53. 53.
    Saidha S, Elamin M, Mullins G, et al.: Treatment of progressive encephalomyelitis with rigidity and myoclonic jerks with rituximab: a case report. Eur J Neurol 2008, 15:e33.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Imperial College, LondonLondonUK

Personalised recommendations